用于将患者分类为异烟肼慢灭活者或快灭活者的磺胺二甲嘧啶乙酰化试验。
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid.
作者信息
Rao K V, Mitchison D A, Nair N G, Prema K, Tripathy S P
出版信息
Br Med J. 1970 Aug 29;3(5721):495-7. doi: 10.1136/bmj.3.5721.495.
Abstract
Sulphadimidine acetylation studies were undertaken in 103 patients, 52 of whom had been classified as slow and 51 as rapid inactivators of isoniazid by a standard microbiological assay method. Each patient received sulphadimidine by mouth in a dose of 44 mg./kg. body weight, and free and total sulphadimidine were estimated in blood and urine collected at six hours. The findings suggest that patients may be classified as slow inactivators of isoniazid if the proportion of acetylated sulphadimidine (total minus free) is (a) less than 25% in blood or (b) less than 70% in urine. The sulphadimidine test is easy to perform and the result is available the same day; urine specimens for the test can be stored at room temperature for over a week without any loss of drug.
摘要
对103名患者进行了磺胺二甲嘧啶乙酰化研究，其中52名患者通过标准微生物检测方法被归类为异烟肼慢灭活者，51名患者被归类为异烟肼快灭活者。每位患者口服磺胺二甲嘧啶，剂量为44毫克/千克体重，在6小时时采集血液和尿液样本，测定游离和总磺胺二甲嘧啶含量。研究结果表明，如果乙酰化磺胺二甲嘧啶（总含量减去游离含量）的比例（a）在血液中低于25%或（b）在尿液中低于70%，那么这些患者可被归类为异烟肼慢灭活者。磺胺二甲嘧啶检测操作简便，当天即可得到结果；检测用的尿液样本可在室温下保存一周以上而药物无任何损失。
相似文献
1
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid.用于将患者分类为异烟肼慢灭活者或快灭活者的磺胺二甲嘧啶乙酰化试验。
Br Med J. 1970 Aug 29;3(5721):495-7. doi: 10.1136/bmj.3.5721.495.
2
Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.同时服用异烟肼对用磺胺二甲嘧啶测定乙酰化代谢表型的影响。
Eur J Clin Pharmacol. 1986;30(4):463-6. doi: 10.1007/BF00607961.
3
Correlation of sulphadimidine acetylation test in urine and blood for isoniazid phenotyping.
Int J Clin Pharmacol Ther Toxicol. 1984 Dec;22(12):646-7.
4
The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine.在捷克斯洛伐克使用磺胺二甲嘧啶测定结核病患者的乙酰化酶表型。
Tubercle. 1973 Mar;54(1):67-71. doi: 10.1016/0041-3879(73)90016-0.
5
N-acetylation phenotyping with sulphadimidine in a Turkish population.
Eur J Clin Pharmacol. 1990;38(1):53-6. doi: 10.1007/BF00314803.
6
Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.接受异烟肼治疗的患者中使用磺胺二甲嘧啶进行乙酰化表型分析。
Int J Clin Pharmacol Res. 1984;4(2):141-4.
7
Possible optimization of sulphadimidine dosage for acetylator phenotyping.磺胺二甲嘧啶剂量用于乙酰化酶表型分析的可能优化
Jpn J Pharmacol. 1991 Aug;56(4):531-4. doi: 10.1254/jjp.56.531.
8
Effect of exercise on plasma levels and urinary excretion of sulphadimidine and procainamide.
Int J Clin Pharmacol Ther Toxicol. 1985 Oct;23(10):548-53.
9
Incidence of isoniazid acetylation phenotypes in North Indians.北印度人群中异烟肼乙酰化表型的发生率。
Int J Clin Pharmacol Ther Toxicol. 1984 May;22(5):259-64.
10
Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.肺结核患者血清与尿液中磺胺二甲嘧啶乙酰化作为异烟肼乙酰化状态预测指标的比较
Indian J Chest Dis Allied Sci. 1996 Jan-Mar;38(1):5-11.
引用本文的文献
1
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.抗结核药物肝毒性的危险因素：一项病例对照研究。
Thorax. 1996 Feb;51(2):132-6. doi: 10.1136/thx.51.2.132.
2
Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.抗结核治疗引起的肝毒性：预测因素的作用
Postgrad Med J. 1995 Jun;71(836):359-62. doi: 10.1136/pgmj.71.836.359.
3
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.人体中某些磺胺类药物乙酰化表型及药代动力学的测定
Clin Pharmacokinet. 1980 May-Jun;5(3):274-94. doi: 10.2165/00003088-198005030-00006.
4
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
J Pharmacokinet Biopharm. 1980 Feb;8(1):53-68. doi: 10.1007/BF01059448.
5
Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution.人类乙酰化酶多态性：利比亚等位基因频率估计及全球分布详情。
J Med Genet. 1981 Oct;18(5):325-30. doi: 10.1136/jmg.18.5.325.
6
[Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
Klin Wochenschr. 1982 May 17;60(10):513-9. doi: 10.1007/BF01756097.
7
Assessment of the drug metabolism capacity of the liver.肝脏药物代谢能力的评估。
Br J Clin Pharmacol. 1982 Nov;14(5):631-51. doi: 10.1111/j.1365-2125.1982.tb04950.x.
8
The use of the autoanalyzer to determine the acetylator phenotype.使用自动分析仪来确定乙酰化酶表型。
J Med Genet. 1972 Mar;9(1):57-9. doi: 10.1136/jmg.9.1.57.
9
A filter paper method for determining isoniazid acetylator phenotype.一种用于确定异烟肼乙酰化酶表型的滤纸法。
Am J Hum Genet. 1974 Jul;26(4):467-73.
10
Simplified method for determining acetylator phenotype.确定乙酰化酶表型的简化方法。
Br Med J. 1972 Aug 26;3(5825):506-7. doi: 10.1136/bmj.3.5825.506.
本文引用的文献
1
Studies of human patterns of isoniazid metabolism using an intravenous fall-off technique with a chemical method.采用静脉滴注技术结合化学方法对异烟肼人体代谢模式进行的研究。
Am Rev Respir Dis. 1960 Jan;81:1-8. doi: 10.1164/arrd.1960.81.1.1.
2
INDIVIDUAL VARIATIONS OF DRUG METABOLISM AS A FACTOR IN DRUG TOXICITY.
Ann N Y Acad Sci. 1965 Mar 12;123:178-87. doi: 10.1111/j.1749-6632.1965.tb12255.x.
3
THE RELATIONSHIP BETWEEN THE CAPACITIES OF HUMAN SUBJECTS TO ACETYLATE ISONIAZID, SULFANILAMIDE AND SULFAMETHAZINE.
Life Sci (1962). 1965 Jan;4:99-107. doi: 10.1016/0024-3205(65)90040-8.
4
A VERTICAL DIFFUSION METHOD FOR THE MICROBIOLOGICAL ASSAY OF ISONIAZID.异烟肼微生物测定的垂直扩散法
J Clin Pathol. 1964 Nov;17(6):622-6. doi: 10.1136/jcp.17.6.622.
5
HUMAN ACETYLATION POLYMORPHISM.人类乙酰化多态性
J Lab Clin Med. 1964 Mar;63:394-403.
6
A NEW METHOD FOR THE DETERMINATION OF N-ACETYL ISONIAZID IN URINE OF AMBULATORY PATIENTS.一种测定门诊患者尿液中N-乙酰异烟肼的新方法。
Am Rev Respir Dis. 1964 Apr;89:587-8. doi: 10.1164/arrd.1964.89.4.587.
7
Genetical and geographic studies on isoniazid inactivation.关于异烟肼失活的遗传学和地理学研究。
Science. 1961 Nov 10;134(3489):1530-1. doi: 10.1126/science.134.3489.1530.
8
Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS.南印度肺结核患者中异烟肼的失活率。2. 单用异烟肼或异烟肼与对氨基水杨酸联合治疗肺结核的临床意义。
Bull World Health Organ. 1961;25(6):779-92.
9
Genetic control of isoniazid metabolism in man.人体中异烟肼代谢的遗传控制。
Br Med J. 1960 Aug 13;2(5197):485-91. doi: 10.1136/bmj.2.5197.485.
10
Deterioration of isoniazid in frozen serum samples: a confirmatory note.冷冻血清样本中异烟肼的降解：一份证实说明。
Am Rev Respir Dis. 1961 Jun;83:906-7. doi: 10.1164/arrd.1961.83.6.906.
Zotero 插件